R&D channel feed – Endpoints News

R&D channel feed

Bluebird bio dives deeper into its TCR alliance with Medigene, adding $500M in milestones and 2 new targets

8 years ago

AstraZeneca's star respiratory drug runs into another wall with COPD, but it's not giving up — yet

8 years ago

Eight years after Eli Lilly dumped it, an upstart biotech has nabbed teplizumab and filed a $56M IPO to back a PhIII comeback

8 years ago

Little vTv once again circles subgroup number, struggling to find something good to say about failed Alzheimer's drug

8 years ago

Roche's big PhIII Tecentriq/Cotellic combo study for colon cancer fails, damaging Exelixis shares

8 years ago

Lipocine shares tumble (again) after the FDA shows another testosterone therapy the door

8 years ago

Can you cut $600M in R&D costs without slash-and-burn tactics? Andy Plump aims to show us how

8 years ago

Daiichi scores in PhIII study of AML drug, beating chemo and building its case for worldwide approvals

8 years ago

Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer's

8 years ago

With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine

8 years ago

Celgene works to calm down anxious investors, promising to re-file ozanimod at the FDA in early 2019

8 years ago

Merck doubles down on Moderna's mRNA cancer vaccines, paying $125M to partner on KRAS shared antigen strategy

8 years ago

FDA motions Alnylam's lumasiran into a PhIII short track, setting up a shot at an OK in '20

8 years ago

Merck study may signal doom for a broad group of pivotal Alzheimer’s studies

8 years ago

Merck’s snapshot of positive data for frontline lung cancer niche triggers a new scramble for quick Keytruda OK

8 years ago

FDA’s back-to-back punches against biosims from Celltrion, Novartis leave Roche’s big Rituxan franchise untouched

8 years ago

Pharma's broken business model — Part 2: Scraping the barrel in drug discovery

8 years ago

High cholesterol contender Esperion slips on safety concerns, stock sinks 30%

8 years ago

Kymriah wins second FDA OK, boosting hope for Novartis' low CAR-T sales

8 years ago

Roche boosts its gene therapy game, expanding partnership with 4D Molecular Therapeutics

8 years ago

Under pressure, Peter Hecht splits Ironwood into two biotechs, spinning out an R&D operation

8 years ago

Gilead joins the lineup of big biopharma partners to ally with Verily — this time focused on immunology

8 years ago

IDO rout: Pivotal trials with Bristol-Myers, Merck and AstraZeneca dumped in wake of Incyte's PhIII implosion

8 years ago

Karyopharm stock soars on selinexor's positive PhIIb update, plans for an NDA

8 years ago

First page Previous page 275 276 277278279 280 281 Next page Last page